References in periodicals archive ?
Urinary Bcl-2 was more accurate in identifying ovarian cancer than was cancer antigen 125 (CA125), which is currently considered the accepted standard for ovarian cancer detection, Dr.
The test utilizes five well-established biomarkers -- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), beta 2-Microglobulin (beta 2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and proprietary software to determine the likelihood of malignancy in women with ovarian mass for whom surgery is planned.
After this initial study, we had some biomarker candidates that, in conjunction with cancer antigen 125 (CA125), [2] appeared to provide a modest improvement over CA125 alone for the detection of early-stage ovarian cancer.
The test utilizes five well-established biomarkers - Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), [eth] 2-Microglobulin ([eth] 2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) - and a proprietary FDA-cleared software device to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.
Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Tumor markers, such as [alpha]-fetoprotein (AFP) [1], carcinoembryonic antigen (CEA), cancer antigen 125 (CA 125), and CA 15-3, can be found in the body (usually blood or urine) when cancer is present (1).